Eyenovia (EYEN) Competitors $1.17 +0.02 (+1.74%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$1.08 -0.09 (-7.26%) As of 05/2/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EYEN vs. LIPO, BCLI, FRTX, GTBP, GNPX, ALBT, NLSP, SNGX, SPRB, and AEZSShould you be buying Eyenovia stock or one of its competitors? The main competitors of Eyenovia include Lipella Pharmaceuticals (LIPO), Brainstorm Cell Therapeutics (BCLI), Fresh Tracks Therapeutics (FRTX), GT Biopharma (GTBP), Genprex (GNPX), Avalon GloboCare (ALBT), NLS Pharmaceutics (NLSP), Soligenix (SNGX), Spruce Biosciences (SPRB), and Aeterna Zentaris (AEZS). These companies are all part of the "pharmaceutical products" industry. Eyenovia vs. Lipella Pharmaceuticals Brainstorm Cell Therapeutics Fresh Tracks Therapeutics GT Biopharma Genprex Avalon GloboCare NLS Pharmaceutics Soligenix Spruce Biosciences Aeterna Zentaris Eyenovia (NASDAQ:EYEN) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk, media sentiment and community ranking. Which has more risk and volatility, EYEN or LIPO? Eyenovia has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Lipella Pharmaceuticals has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500. Does the media prefer EYEN or LIPO? In the previous week, Eyenovia's average media sentiment score of 1.00 beat Lipella Pharmaceuticals' score of 0.00 indicating that Eyenovia is being referred to more favorably in the media. Company Overall Sentiment Eyenovia Positive Lipella Pharmaceuticals Neutral Does the MarketBeat Community believe in EYEN or LIPO? Eyenovia received 173 more outperform votes than Lipella Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Lipella Pharmaceuticals an outperform vote while only 64.21% of users gave Eyenovia an outperform vote. CompanyUnderperformOutperformEyenoviaOutperform Votes17464.21% Underperform Votes9735.79% Lipella PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo Votes Do insiders and institutionals hold more shares of EYEN or LIPO? 25.8% of Eyenovia shares are held by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are held by institutional investors. 7.1% of Eyenovia shares are held by company insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is EYEN or LIPO more profitable? Lipella Pharmaceuticals has a net margin of -882.82% compared to Eyenovia's net margin of -114,639.41%. Lipella Pharmaceuticals' return on equity of -192.33% beat Eyenovia's return on equity.Company Net Margins Return on Equity Return on Assets Eyenovia-114,639.41% -1,108.24% -139.36% Lipella Pharmaceuticals -882.82%-192.33%-154.24% Do analysts prefer EYEN or LIPO? Eyenovia currently has a consensus target price of $2.00, suggesting a potential upside of 70.94%. Given Eyenovia's stronger consensus rating and higher possible upside, research analysts plainly believe Eyenovia is more favorable than Lipella Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eyenovia 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Lipella Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better earnings & valuation, EYEN or LIPO? Lipella Pharmaceuticals has higher revenue and earnings than Eyenovia. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Eyenovia, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEyenovia$57.34K57.75-$27.26M-$58.40-0.02Lipella Pharmaceuticals$536.36K11.98-$4.62M-$4.72-0.53 SummaryEyenovia and Lipella Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Eyenovia News Delivered to You Automatically Sign up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EYEN vs. The Competition Export to ExcelMetricEyenoviaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.31M$6.85B$5.55B$8.03BDividend YieldN/A2.96%5.09%4.23%P/E Ratio-0.027.4722.7118.87Price / Sales57.75258.42405.55106.92Price / CashN/A65.8538.1834.62Price / Book0.076.566.794.34Net Income-$27.26M$143.41M$3.22B$248.06M7 Day Performance7.34%3.37%3.34%3.21%1 Month Performance5.41%10.31%6.90%8.30%1 Year Performance-98.55%-3.67%16.21%5.06% Eyenovia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EYENEyenovia2.5557 of 5 stars$1.17+1.7%$2.00+70.9%-98.4%$3.31M$57,336.00-0.0240Short Interest ↓Positive NewsLIPOLipella Pharmaceuticals1.4569 of 5 stars$2.28-5.0%N/A-58.0%$5.81M$536,357.00-0.544Upcoming EarningsPositive NewsGap DownBCLIBrainstorm Cell Therapeutics3.6731 of 5 stars$0.86-1.8%$30.00+3,388.4%-78.9%$5.61MN/A-0.1840Positive NewsGap UpFRTXFresh Tracks TherapeuticsN/A$0.94-0.5%N/A+2.7%$5.59M$10.06M-0.6620GTBPGT Biopharma3.3233 of 5 stars$2.17-4.4%$11.00+406.9%-27.1%$5.50MN/A-0.318Short Interest ↓Positive NewsGap DownGNPXGenprex4.0072 of 5 stars$0.23-6.2%$10.00+4,342.5%-87.7%$5.44MN/A0.0020Gap UpALBTAvalon GloboCare1.069 of 5 stars$3.23-9.5%N/A+0.2%$5.34M$1.31M-0.165Short Interest ↑NLSPNLS PharmaceuticsN/A$1.45-0.7%N/A+1,069.3%$5.22MN/A0.006SNGXSoligenix0.2773 of 5 stars$2.07-1.4%N/A-70.6%$5.20M$840,000.00-0.2720Upcoming EarningsSPRBSpruce Biosciences2.227 of 5 stars$0.12+2.1%$2.17+1,687.7%-90.0%$5.12M$7.10M-0.1320Analyst RevisionGap DownHigh Trading VolumeAEZSAeterna ZentarisN/A$2.83+0.3%N/A-53.4%$5.07M$2.37M-0.1920Analyst ForecastNews Coverage Related Companies and Tools Related Companies LIPO Competitors BCLI Competitors FRTX Competitors GTBP Competitors GNPX Competitors ALBT Competitors NLSP Competitors SNGX Competitors SPRB Competitors AEZS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EYEN) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyenovia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyenovia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EYEN Stock Free EYEN Stock Alerts